Metastatic pancreatic cancer: Are we making progress in treatment?

Gastroenterology Research and Practice

Volumn , Issue , 2012, Pages

  Chiu, Joanne ^a   Yau, Thomas ^a,b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; LONAFARNIB; OXALIPLATIN; PACLITAXEL; PLACEBO; SORAFENIB; TIPIFARNIB;

ADVANCED CANCER; ADVANCED PANCREATIC CANCER; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MOLECULARLY TARGETED THERAPY; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; VOMITING;

EID: 84871384069     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2012/898931     Document Type: Review

References (41)

1. Glimelius B., Hoffman K., Sjödén P. O., Jacobsson G., Sellström H., Enander L. K., Linné T., Svensson C., Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Annals of Oncology 1996 7 6 593 600 2-s2.0-0029816590 (Pubitemid 26285639)
2. Burris H. A. III, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P., Nelson R., Dorr F. A., Stephens C. D., Von Hoff D. D., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 1997 15 6 2403 2413 2-s2.0-8244254377 (Pubitemid 27251144)
3. Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., Adenis A., Raoul J. L., Gourgou-Bourgade S., de la Fouchardière C., Bennouna J., Bachet J. B., Khemissa-Akouz F., Péré-Vergé D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine 2011 364 19 1817 1825 2-s2.0-79955921754 10.1056/NEJMoa1011923
4. Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schönekäs H., Rost A., Neuhaus H., Haag C., Clemens M., Heinrich B., Vehling-Kaiser U., Fuchs M., Fleckenstein D., Gesierich W., Uthgenannt D., Einsele H., Holstege A., Hinke A., Schalhorn A., Wilkowski R., Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of Clinical Oncology 2006 24 24 3946 3952 2-s2.0-33748445708 10.1200/JCO.2005.05.1490 (Pubitemid 46630743)
5. Poplin E., Feng Y., Berlin J., Rothenberg M. L., Hochster H., Mitchell E., Alberts S., O'Dwyer P., Haller D., Catalano P., Cella D., Benson A. B., Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern cooperative oncology group. Journal of Clinical Oncology 2009 27 23 3778 3785 2-s2.0-68949114505 10.1200/JCO.2008.20.9007
6. Heinemann V., Labianca R., Hinke A., Louvet C., Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Annals of Oncology 2007 18 10 1652 1659 2-s2.0-34948888231 10.1093/annonc/mdm283 (Pubitemid 47514482)
7. Berlin J. D., Catalano P., Thomas J. P., Kugler J. W., Haller D. G., Benson A. B., Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern cooperative oncology group trial E2297. Journal of Clinical Oncology 2002 20 15 3270 3275 2-s2.0-0036682041 10.1200/JCO.2002.11.149 (Pubitemid 34831525)
8. Sultana A., Smith C. T., Cunningham D., Starling N., Neoptolemos J. P., Ghaneh P., Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses. British Journal of Cancer 2008 99 1 6 13 2-s2.0-46349088061 10.1038/sj.bjc.6604436 (Pubitemid 351920234)
9. Cunningham D., Chau I., Stocken D. D., Valle J. W., Smith D., Steward W., Harper P. G., Dunn J., Tudur-Smith C., West J., Falk S., Crellin A., Adab F., Thompson J., Leonard P., Ostrowski J., Eatock M., Scheithauer W., Herrmann R., Neoptolemos J. P., Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology 2009 27 33 5513 5518 2-s2.0-73949135518 10.1200/JCO.2009.24.2446
10. Bernhard J., Dietrich D., Scheithauer W., Gerber D., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schüller J., Saletti P., Bauer J., Figer A., Pestalozzi B. C., Köhne C. H., Mingrone W., Stemmer S. M., Tàmas K., Kornek G. V., Koeberle D., Herrmann R., Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial-SAKK 44/00-CECOG/PAN.1.3.001. Journal of Clinical Oncology 2008 26 22 3695 3701 2-s2.0-49249108437 10.1200/JCO.2007.15.6240
11. Herrmann R., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schüller J., Saletti P., Bauer J., Figer A., Pestalozzi B., Köhne C. H., Mingrone W., Stemmer S. M., Tàmas K., Kornek G. V., Koeberle D., Cina S., Bernhard J., Dietrich D., Scheithauer W., Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the central European cooperative oncology group. Journal of Clinical Oncology 2007 25 16 2212 2217 2-s2.0-34250180939 10.1200/JCO.2006.09.0886 (Pubitemid 46954645)
12. Heinemann V., Boeck S., Hinke A., Labianca R., Louvet C., Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008 8, article 82 2-s2.0-42349093032 10.1186/1471-2407-8-82 (Pubitemid 351552578)
13. Sultana A., Smith C. T., Cunningham D., Starling N., Neoptolemos J. P., Ghaneh P., Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. Journal of Clinical Oncology 2007 25 18 2607 2615 2-s2.0-34247188535 10.1200/JCO.2006.09.2551 (Pubitemid 47041235)
14. Vaccaro V., Sperduti I., Milella M., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine 2011 365 8 768 769 10.1056/NEJMc1107627
15. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M., Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988 53 4 549 554 2-s2.0-0024292722
16. Hezel A. F., Kimmelman A. C., Stanger B. Z., Bardeesy N., DePinho R. A., Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development 2006 20 10 1218 1249 2-s2.0-33646577163 10.1101/gad.1415606 (Pubitemid 43727584)
17. Jones S., Zhang X., Parsons D. W., Lin J. C. H., Leary R. J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S. M., Fu B., Lin M. T., Calhoun E. S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D. R., Hidalgo M., Leach S. D., Klein A. P., Jaffee E. M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J. R., Kern S. E., Hruban R. H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V. E., Kinzler K. W., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008 321 5897 1801 1806 2-s2.0-52149123619 10.1126/science.1164368
18. Cohen S. J., Ho L., Ranganathan S., Abbruzzese J. L., Alpaugh R. K., Beard M., Lewis N. L., McLaughlin S., Rogatko A., Perez-Ruixo J. J., Thistle A. M., Verhaeghe T., Wang H., Weiner L. M., Wright J. J., Hudes G. R., Meropol N. J., Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology 2003 21 7 1301 1306 2-s2.0-0038413837 10.1200/JCO.2003.08.040 (Pubitemid 46606407)
19. Macdonald J. S., McCoy S., Whitehead R. P., Iqbal S., Wade J. L., Giguere J. K., Abbruzzese J. L., A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Investigational New Drugs 2005 23 5 485 487 2-s2.0-23844517889 10.1007/s10637-005-2908-y (Pubitemid 41160096)
20. van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne W. L., Szawlowski A., Schoffski P., Post S., Verslype C., Neumann H., Safran H., Humblet Y., Perez Ruixo J., Ma Y., Von Hoff D., Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. Journal of Clinical Oncology 2004 22 8 1430 1438 2-s2.0-2342645506 10.1200/JCO.2004.10.112 (Pubitemid 41103625)
21. Lersch C., van Cutsem E., Amado R., Randomized phase II study of SCH, 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proceedings-American Society of Clinical Oncology 2001 20 abstract no. 608
22. Tobita K., Kijima H., Dowaki S., Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. International Journal of Molecular Medicine 2003 11 3 305 309
23. Moore M. J., Goldstein D., Hamm J., Figer A., Hecht J. R., Gallinger S., Au H. J., Murawa P., Walde D., Wolff R. A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. Journal of Clinical Oncology 2007 25 15 1960 1966 2-s2.0-34249933404 10.1200/JCO.2006.07.9525 (Pubitemid 46972777)
24. Xiong H. Q., Rosenberg A., LoBuglio A., Schmidt W., Wolff R. A., Deutsch J., Needle M., Abbruzzese J. L., Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. Journal of Clinical Oncology 2004 22 13 2610 2616 2-s2.0-4344590997 10.1200/JCO.2004.12.040 (Pubitemid 41103748)
25. Philip P. A., Benedetti J., Corless C. L., Wong R., O'Reilly E. M., Flynn P. J., Rowland K. M., Atkins J. N., Mirtsching B. C., Rivkin S. E., Khorana A. A., Goldman B., Fenoglio-Preiser C. M., Abbruzzese J. L., Blanke C. D., Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest oncology group-directed intergroup trial S0205. Journal of Clinical Oncology 2010 28 22 3605 3610 2-s2.0-77955914277 10.1200/JCO.2009.25.7550
26. Kim G. P., Foster N. R., Salim M., Flynn P. J., Moore D. F., Zon R., Mowat R. B., Wiesenfeld M., McCullough A. E., Alberts S. R., Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology 2011 29 supplement, abstract no. 4030
27. Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K., High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000 88 10 2239 2245 (Pubitemid 30247122)
28. Kindler H. L., Niedzwiecki D., Hollis D., Sutherland S., Schrag D., Hurwitz H., Innocenti F., Mulcahy M. F., O'Reilly E., Wozniak T. F., Picus J., Bhargava P., Mayer R. J., Schilsky R. L., Goldberg R. M., Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). Journal of Clinical Oncology 2010 28 22 3617 3622 2-s2.0-77955887676 10.1200/JCO.2010.28.1386
29. van Cutsem E., Vervenne W. L., Bennouna J., Humblet Y., Gill S., van Laethem J. L., Verslype C., Scheithauer W., Shang A., Cosaert J., Moore M. J., Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of Clinical Oncology 2009 27 13 2231 2237 2-s2.0-65549150854 10.1200/JCO.2008.20.0238
30. Kindler H. L., Ioka T., Richel D. J., Bennouna J., Létourneau R., Okusaka T., Funakoshi A., Furuse J., Park Y. S., Ohkawa S., Springett G. M., Wasan H. S., Trask P. C., Bycott P., Ricart A. D., Kim S., Van Cutsem E., Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. The Lancet Oncology 2011 12 3 256 262 2-s2.0-79952036599 10.1016/S1470-2045(11) 70004-3
31. Riess H., Double-blind, placebo-controlled randomized phase III trial of aflibercept (A) plus gemcitabine (G) versus placebo (P) plus gemcitabine (G) in patients with metastatic pancreatic cancer: final results. Proceedings of the European Society for Medical Oncology's 12th World Congress on Gastrointestinal Cancer 2010 Barcelona, Spain
32. Goncalves A., Gilabert M., François E., BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals of Oncology 2012 23 11 2799 2805 10.1093/annonc/mds135
33. Erkan M., Reiser-Erkan C., Michalski C. W., Kleeff J., Tumor microenvironment and progression of pancreatic cancer. Experimental Oncology 2010 32 3 128 131 2-s2.0-77957726424
34. Von Hoff D. D., Ramanathan R. K., Borad M. J., Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Journal of Clinical Oncology 2011 29 34 4548 4554
35. Bergmann U., Funatomi H., Yokoyama M., Beger H. G., Korc M., Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Research 1995 55 10 2007 2011 2-s2.0-0028997487
36. Freeman J. W., Mattingly C. A., Strodel W. E., Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF- β type RII receptor. Journal of Cellular Physiology 1995 165 1 155 163 2-s2.0-0028793568 10.1002/jcp.1041650118
37. Hanks B. A., Holtzhausen A., Gimpel P., Effect of the loss of the type III TGF β receptor during tumor progression on tumor microenvironment: preclinical development of TGF β inhibition and TGF β -related biomarkers to enhance immunotherapy efficacy. Journal of Clinical Oncology 2012 30 supplement, abstract no. 10563
38. Wasan H. S., Springett G. M., Chodkiewicz C., Wong R., Maurel J., Barone C., Rosbrook B., Ricart A. D., Kim S., Spano J. P., CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. British Journal of Cancer 2009 101 7 1162 1167 2-s2.0-70349663751 10.1038/sj.bjc.6605243
39. García-Manteiga J., Molina-Arcas M., Casado F. J., Mazo A., Pastor-Anglada M., Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′2′-difluorodeoxycytidine-induced cytotoxicity. Clinical Cancer Research 2003 9 13 5000 5008 2-s2.0-0142219312 (Pubitemid 37323307)
40. Giovannetti E., del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., Orlandini C., Boggi U., Campani D., Del Chiaro M., Iannopollo M., Bevilacqua G., Mosca F., Danesi R., Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Research 2006 66 7 3928 3935 2-s2.0-33645731188 10.1158/0008-5472.CAN-05-4203
41. Nakano Y., Tanno S., Koizumi K., Nishikawa T., Nakamura K., Minoguchi M., Izawa T., Mizukami Y., Okumura T., Kohgo Y., Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. British Journal of Cancer 2007 96 3 457 463 2-s2.0-33846816556 10.1038/sj.bjc.6603559 (Pubitemid 46215217)